Recent reports have demonstrated that the activation of canonical Wnt/β-catenin signaling programs DCs to a tolerogenic state by regulating the secretion of factors such as interleukin-6 (IL-6), IL-12, and IL-10; that way, Wnt/β-catenin signaling limits the occurrence of autoimmune diseases in clinical settings and in animal models, such as experimental autoimmune encephalomyelitis (EAE), inflammatory bowel disease, and rheumatoid arthritis (RA) [9–12]. This evidence concerns the gene IL10 and rheumatoid arthritis.